VRTXNASDAQ— Vertex Pharmaceuticals Inc Price & Analysis

Vertex Pharmaceuticals Inc

HEALTHCARE — BIOTECHNOLOGY

$523.93

-$11.24-2.10%

Market Cap: $135.64B; Large Cap
P/E Ratio: 30.55; Fwd: 24.1
EPS (TTM): $17.52
Div. Yield: N/A

Technical Summary

RSI (14)55.07Neutral

SMA (50)$522.71Bullish

SMA (200)$477.37Bullish

MACD0.7421Bullish

Bollinger$486.40 – $534.89Mid

Stochastic86.72Overbought

Theo Outlook

Vertex Pharmaceuticals Inc is an American biopharmaceutical company based in Boston, Massachusetts. As of June 30, 2026, trailing twelve months revenue stood at $12.59 billion, profit margin at 35%, earnings per share at $17.52, and market capitalization at $135.64 billion.

Bull case: Quarterly revenue grew 12.5% year over year and quarterly earnings grew 8% year over year as of June 30, 2026, while operating margin reached 38.1%. Bear case: Trailing price to earnings ratio was 30.55 and forward price to earnings ratio was 24.1 as of June 30, 2026.

Main risks center on the biotechnology sector's characteristics shown in a beta of 0.281 as of June 30, 2026. Analysis generated by HeyTheo AI from company and market data. It may be incomplete or inaccurate.

Analysis generated by HeyTheo AI on Oct 23, 2026.

Company Overview

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Fundamental Snapshot

Revenue: $12.59B
EBITDA: $5.10B
Gross Profit: $6.92B
Operating Margin: 38.1%
Profit Margin: 35.0%
ROE: 23.5%
Book Value: $79.92
Beta: 0.28
52-Wk High: $560.25
52-Wk Low: $403.16
Volume: 830.74K
PEG Ratio: 1.9

Frequently Asked Questions

What does Vertex Pharmaceuticals do?

Vertex Pharmaceuticals Inc is an American biopharmaceutical company based in Boston, Massachusetts. The company operates in the biotechnology industry within the healthcare sector as of June 30, 2026.

Where does Vertex Pharmaceuticals's revenue come from?

The tool output provides no breakdown of revenue sources as of June 30, 2026. Trailing twelve months revenue per share was $49.51 on that date.

How does Vertex Pharmaceuticals compete?

The tool output provides no information on competitive positioning as of June 30, 2026. Return on equity stood at 23.5% and return on assets at 11.9% for the trailing twelve months on that date.

What are the main risks for Vertex Pharmaceuticals?

The tool output provides no explicit risk factors as of June 30, 2026. Beta measured 0.281 on that date.

How is Vertex Pharmaceuticals valued?

As of June 30, 2026, trailing price to earnings ratio was 30.55, forward price to earnings ratio was 24.1, price to sales ratio was 10.77, and price to book ratio was 6.46. Enterprise value to revenue was 9.93 and enterprise value to EBITDA was 24.51 on that date.